(19)
(11) EP 3 420 077 A1

(12)

(43) Date of publication:
02.01.2019 Bulletin 2019/01

(21) Application number: 17757316.9

(22) Date of filing: 24.02.2017
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
C12N 15/113(2010.01)
A61P 31/12(2006.01)
G01N 33/574(2006.01)
C12N 15/09(2006.01)
C12N 15/12(2006.01)
A61K 9/127(2006.01)
C07H 21/04(2006.01)
(86) International application number:
PCT/US2017/019390
(87) International publication number:
WO 2017/147446 (31.08.2017 Gazette 2017/35)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 25.02.2016 US 201662299792 P
25.02.2016 US 201662299839 P

(71) Applicant: Agenovir Corporation
South San Francisco, California 94080 (US)

(72) Inventors:
  • QUAKE, Stephen, R.
    South San Francisco, CA 94080 (US)
  • SLOAN, Derek, D.
    Belmont, CA 94002 (US)
  • XIONG,Xin Cindy
    San Mateo, CA 94403 (US)

(74) Representative: Eisenführ Speiser 
Patentanwälte Rechtsanwälte PartGmbB Postfach 31 02 60
80102 München
80102 München (DE)

   


(54) VIRAL AND ONCOVIRAL NUCLEASE TREATMENT